Table 2.

RALISE domains at the baseline, 10-20 and 30 days from the start of treatment.

	First evaluation	10 days	20 days	30 days
VAS	7 (4.75–8)	3 (1–5)	1 (0–3.25)	0 (0–1.25)
		p < 0.005	p = 0.05	p < 0.05
Pain duration	2 (1–4)	1 (1–1.25)	1 (1–1)	1 (1–1)
		p < 0.005	p = 0.239	p = 0.239
NSAID use
- Never	25 (69.5%)	33 (92%)	34 (94%)	34 (94%)
- Rarely	6 (16.5%)	3 (8%)	1 (3%)	1 (3%)
- Sometimes	2 (5.5%)	0	1 (3%)	0 (3%)
- Often	2 (5.5%)	0	0	1
- Alwalys	1 (3%)	0	0	0
		p < 0.005	p = 0.05	p < 0.05
Bleeding
- Never	14 (39%)	28 (78%)	32 (89%)	31 (86%)
- Rarely	11 (31%)	8 (22%)	4 (11%)	4 (11%)
- Sometimes	6 (16.5%)	0	0	0
- Often	3 (8%)	0	0	1 (3%)
- Alwalys	2 (5.5%)	0	0	0
		p < 0.005	p = 0.21	p = 0.54
QoL
- No impact	4 (11%)	10 (28%)	21 (58%)	26 (72.5%)
- Slightly	5 (14.5%)	13 (36%)	11 (31%)	6 (16.5%)
- Moderately	8 (22%)	12 (33%)	4 (11%)	3 (8%)
- Considerably	16 (44.5%)	1 (3%)	0	1 (3%)
- Severely	3 (8%)	0	0	0
		p < 0.005	p < 0.005	p = 0.64
REALISE	15 (11–19.25)	8 (6–11)	6 (4.75–9.25)	4 (4–6)
		p < 0.005	p < 0.05	p = 0.139